JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS)

Epidemiology of Anti-JCV Antibody Prevalence in Multiple Sclerosis Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01185717

Acronym

JEMS

Enrollment

7726

Registered

2010-08-20

Start date

2010-09-30

Completion date

2012-06-30

Last updated

2014-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Brief summary

The objective of the study is to estimate the prevalence of anti-JCV antibodies in multiple sclerosis (MS) participants.

Detailed description

This is a cross-sectional, multi-center, multi-national, epidemiological study to estimate the prevalence of anti-JCV antibody in MS participants. This study will provide an estimate of the prevalence of anti-JCV antibody in the MS population and will investigate inter-country differences.

Interventions

None listed

Study design

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: * All candidates for this study must have the ability to understand the purpose of the study and provide signed and dated informed consent. * All patients with a diagnosis of Multiple Sclerosis (MS) of any type, irrespective of their treatment, are eligible to participate once. Key

Exclusion criteria

* None NOTE: Other protocol defined Inclusion/

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of anti-JCV antibodies	Single timepoint (Day 1)	Prevalence of anti-JCV antibodies will be estimated as the number of participants with anti-JCV antibodies detected in serum divided by the total number of participants with a serum sample that was evaluated.

Outcome results